227 related articles for article (PubMed ID: 34261380)
21. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
22. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
[TBL] [Abstract][Full Text] [Related]
23. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
24. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Gouni-Berthold I; Alexander VJ; Yang Q; Hurh E; Steinhagen-Thiessen E; Moriarty PM; Hughes SG; Gaudet D; Hegele RA; O'Dea LSL; Stroes ESG; Tsimikas S; Witztum JL;
Lancet Diabetes Endocrinol; 2021 May; 9(5):264-275. PubMed ID: 33798466
[TBL] [Abstract][Full Text] [Related]
26. Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen.
Gesner M; Frishman WH
Cardiol Rev; 2023 Nov-Dec 01; 31(6):325-329. PubMed ID: 36129324
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
[TBL] [Abstract][Full Text] [Related]
28. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
[TBL] [Abstract][Full Text] [Related]
29. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
[TBL] [Abstract][Full Text] [Related]
30. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
Baass A; Paquette M; Bernard S; Hegele RA
J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
[TBL] [Abstract][Full Text] [Related]
31. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.
Chyzhyk V; Brown AS
Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
33. Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I; Schwarz J; Berthold HK
Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
[TBL] [Abstract][Full Text] [Related]
34. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
[TBL] [Abstract][Full Text] [Related]
35. Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome.
Larouche M; Brisson D; Morissette MC; Gaudet D
Orphanet J Rare Dis; 2023 Jun; 18(1):167. PubMed ID: 37370069
[TBL] [Abstract][Full Text] [Related]
36. Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen.
Isaac RH; Gonzalez-Devia D; Mendivil CO; Chapman E
Front Allergy; 2023; 4():1201807. PubMed ID: 37361109
[TBL] [Abstract][Full Text] [Related]
37. Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA; Do R; Rosenson RS
Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
[TBL] [Abstract][Full Text] [Related]
38. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
[TBL] [Abstract][Full Text] [Related]
39. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
40. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
